Managing Severe Asthma in the Era of Biologics: Early-Onset Asthma
Jointly provided by
This educational activity is supported by an educational grant from GlaxoSmithKline.
Release date: 4/17/2020
Expiration date: 4/17/2021
Estimated time to complete: 0.5 hour
In recent years, better understanding of asthma pathophysiology has led to the development of targeted biologics that have improved outcomes for some patients with severe asthma, and the Global Initiative for Asthma (GINA) guidelines now include biologics as a part of its stepwise treatment guidelines for personalized therapy. However, physicians continue to face challenges in determining when to start biologic therapy and which therapy to choose to most effectively manage their patients’ severe asthma symptoms.
In this activity, learners will meet Theresa, a 30-year-old woman who was diagnosed with asthma in infancy and whose asthma has been getting worse over the last several months.
This activity provides guidance in the following areas:
- Determining whether it is appropriate to initiate biologic treatment
- Navigating challenges when prescribing biologic therapies
- Tailoring treatment using the most appropriate targeted biologic agent based on patient phenotype and endotype.
Following the case presentation, learners will test their ability to apply what they have learned about managing severe asthma in Cranium Challenge.
Reynold A. Panettieri, Jr., MD—Program Chair
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, New Jersey
Emeritus Professor of Medicine, University of Pennsylvania
Flavia C. Hoyte, MD
Associate Professor of Medicine
Allergy/Immunology Fellowship Training Program
Division of Allergy/Immunology
National Jewish Health
University of Colorado
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
National Jewish Health
This activity has been designed to meet the educational needs of allergists, immunologists, pulmonologists, and primary care providers (including nurse practitioners and physician assistants) involved in the care of patients with severe asthma.
Upon completion of this activity, participants should be able to:
- Recognize clinical characteristics that indicate that a patient is a candidate for targeted biologic therapy
- Overcome challenges to implementing biologic therapy in practice
- Differentiate the efficacy characteristics of biologic therapies using current and emerging data to better personalize treatment according to the phenotypic characteristics and outstanding clinical treatment needs of each patient
Accreditation Statement (from the ACCME)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement (from the AMA):
The University of Cincinnati designates this enduring material activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification Points Statement
American Board of Internal Medicine Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
In accordance with the ACCME Standards for Commercial Support, all CE providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CE activity content over which the individual has control. Relationship information appears below:Faculty
Flavia C. Hoyte, MD, has disclosed the following relevant financial relationships:
Scientific Advisory Board: Genentech
Reynold A. Panettieri, Jr., MD, has disclosed the following relevant financial relationships:
Grant/Research Support: AstraZeneca, Equillium, Genentech, MedImmune, OncoArendi Therapeutics, Research Institute for Fragrance Materials, Teva Pharmaceuticals USA, Theratrophix
Speakers Bureau: AstraZeneca, Genentech, Sanofi Genzyme/Regeneron Pharmaceuticals
Scientific Advisory Board: AstraZeneca, Avillion, Boehringer Ingelheim Pharmaceuticals, Equillium, MedImmune, Research Institute for Fragrance Materials, Theravance Biopharma
Michael E. Wechsler, MD, MMSc, has disclosed the following relevant financial relationships:
Consultant: AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA
University of Cincinnati
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Yvette Murley, PhD, Medical Director, has disclosed no relevant financial relationships.
Heather Rafa, Program Manager, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, RedMedEd, and GlaxoSmithKline do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, RedMedEd, or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 66% or greater) and program evaluation. Certificates can be printed immediately.
Contact InformationFor questions regarding CME credit, contact the University of Cincinnati at 513.558.7277 or email@example.com.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or firstname.lastname@example.org.
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
© 2020. This CME-certified program is held as copyrighted by the University of Cincinnati and RedMedEd. Through this notice, the University of Cincinnati and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.